Amgen looks to expand access to Otezla in the US
Amgen has submitted a supplemental new drug application (sNDA) seeking expanded approval for Otezla in adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.
February 24, 2021
by pharmatimes
Risankizumab trials show higher clinical remission in patients with Crohn’s disease
Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn’s disease.
January 12, 2021
by europeanpharmaceuticalreview
Amgen Announces Positive Top-Line Results from Otezla Plaque Psoriasis Study
Amgen announced positive top-line results from the ADVANCE trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla® (apremilast) in adults with mild-to-moderate plaque psoriasis.
May 8, 2020
by americanpharmaceuticalreview
Orum Therapeutics raises $30M to advance Ab technology
Financing proceeds to fund further platform development and therapeutic discovery in cancer and rare diseases
July 22, 2019
by fiercepharma
Merck joins TRANSVAC2 programme to advance vaccine development
TRANSVAC2, part of the EU's Horizon 2020 program, provides trainings to streamline vaccine manufacturing and development
May 21, 2019
by biospectrumasia
FDA takes new steps to advance natural history studies for accelerating novel treatments for rare diseases
One key way we’ve addressed these opportunities is by providing funding for rare disease natural history ……
March 23, 2019
by firstwordpharma